Skip to main content
Onconic Therapeutics Inc. logo

Onconic Therapeutics Inc. — Investor Relations & Filings

Ticker · 476060 ISIN · KR7476060009 KO Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2025-01-23 Regulatory Filings
Country KR South Korea
Listing KO 476060

About Onconic Therapeutics Inc.

http://onconic.co.kr/

Onconic Therapeutics Inc., established in 2020, is a biopharmaceutical company specializing in the research and development of innovative drugs. A subsidiary of Jeil Pharmaceutical, the company focuses on creating novel treatments for cancer and gastrointestinal disorders, including gastroesophageal reflux disease. Its development strategy prioritizes therapeutics for conditions with high unmet medical needs and significant market potential. Onconic Therapeutics actively advances its pipeline of drug candidates through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (국산신약 37호 자큐보정의 품목허가사항 변경허가 신청(위궤양 신규적응증 추가를 위한 한국 식품의약품안전처 허가신청))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Onconic Therapeutics regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for a change in product approval for their drug 'Zakyuvo' to include a new indication (gastric ulcer) with the Korean Ministry of Food and Drug Safety. This is a standard regulatory disclosure of a material business event. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory announcement, it is classified as a Regulatory Filing (RNS).
2025-01-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as an 'Insider Trading Report' or 'Director's Dealing' report) where executives or major shareholders disclose changes in their shareholdings. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2024-12-27 Korean
투자판단관련주요경영사항 (파트너사인 Livzon Pharmaceutical Group Inc.의 Zastaprazan(자큐보정) 중국 임상3상 시험 첫 환자 투여에 따른 마일스톤 기술료 청구 )
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Onconic Therapeutics) regarding a 'major management matter' (투자판단 관련 주요경영사항). It details the achievement of a clinical trial milestone by a partner company, resulting in a milestone payment claim. This type of disclosure is a standard regulatory announcement for material events in the Korean market, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, dividends, or financial reports.
2024-12-23 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report or major shareholding notification). It details the acquisition and disposal of shares by Stonebridge Ventures Inc. and its related investment funds in Onconic Therapeutics. This falls under the 'Major Shareholding Notification' category.
2024-12-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in Korea. This type of filing is used to disclose changes in share ownership by major shareholders or insiders, which corresponds to the 'Major Shareholding Notification' (MRQ) category in the provided schema.
2024-12-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of Jeil Pharmaceutical Co., Ltd. in Onconic Therapeutics, following the latter's new listing on the KOSDAQ. This document type is specifically used to notify the market of significant ownership stakes and changes in control, which falls under the 'Major Shareholding Notification' category.
2024-12-23 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.